ERBB2 and breast carcinoma: These results confirm the findings of the I-SPY2 study (37), which showed that the addition of pembrolizumab or doxorubicin to neoadjuvant chemotherapy in patients with ER+/HER2-, MammaPrint high-risk breast cancers increased the pCR rate (38, 39).